Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

ZYDUS LIFESCIENCES 2023-24 Annual Report Analysis
Wed, 17 Jul

ZYDUS LIFESCIENCES has announced its results for the year ended March 2024. Let us have a look at the detailed performance review of the company during FY23-24.

ZYDUS LIFESCIENCES Income Statement Analysis

  • Operating income during the year rose 13.4% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 78.1% YoY during the fiscal. Operating profit margins witnessed a fall and down at 27.0% in FY24 as against 17.2% in FY23.
  • Depreciation charges increased by 5.7% and finance costs decreased by 37.5% YoY, respectively.
  • Other income declined by 22.2% YoY.
  • Net profit for the year grew by 91.4% YoY.
  • Net profit margins during the year grew from 11.6% in FY23 to 19.6% in FY24.

ZYDUS LIFESCIENCES Income Statement 2023-24

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Net Sales Rs m 172,374 195,474 13.4%
Other income Rs m 4,746 3,694 -22.2%
Total Revenues Rs m 177,120 199,168 12.4%
Gross profit Rs m 29,677 52,848 78.1%
Depreciation Rs m 7,227 7,641 5.7%
Interest Rs m 1,299 812 -37.5%
Profit before tax Rs m 25,897 48,089 85.7%
Tax Rs m 5,878 9,775 66.3%
Profit after tax Rs m 20,019 38,314 91.4%
Gross profit margin % 17.2 27.0
Effective tax rate % 22.7 20.3
Net profit margin % 11.6 19.6
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Must See: These Segments are Witnessing Incredible Growth with Modi's Push

ZYDUS LIFESCIENCES Balance Sheet Analysis

  • The company's current liabilities during FY24 down at Rs 53 billion as compared to Rs 55 billion in FY23, thereby witnessing an decrease of -3.4%.
  • Current assets rose 14% and stood at Rs 114 billion, while fixed assets rose 11% and stood at Rs 161 billion in FY24.
  • Overall, the total assets and liabilities for FY24 stood at Rs 276 billion as against Rs 245 billion during FY23, thereby witnessing a growth of 13%.

ZYDUS LIFESCIENCES Balance Sheet as on March 2024

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Networth Rs m 175,158 198,295 13.2
 
Current Liabilities Rs m 55,267 53,397 -3.4
Long-term Debt Rs m 0 0 0.0
Total Liabilities Rs m 244,940 276,366 12.8
 
Current assets Rs m 100,082 114,198 14.1
Fixed Assets Rs m 144,776 161,352 11.4
Total Assets Rs m 244,940 276,366 12.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



ZYDUS LIFESCIENCES Cash Flow Statement Analysis

  • ZYDUS LIFESCIENCES's cash flow from operating activities (CFO) during FY24 stood at Rs 32 billion, an improvement of 20.0% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY24 stood at Rs -15 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY24 stood at Rs -18 billion, an improvement of 59% on a YoY basis.
  • Overall, net cash flows for the company during FY24 stood at Rs -748 million from the Rs -2 billion net cash flows seen during FY23.

ZYDUS LIFESCIENCES Cash Flow Statement 2023-24

Particulars No. of months 12 12 % Change
Year Ending Mar-23 Mar-24
Cash Flow from Operating Activities Rs m 26,888 32,279 20.0%
Cash Flow from Investing Activities Rs m 15,350 -14,752 -
Cash Flow from Financing Activities Rs m -44,004 -18,104 -
Net Cash Flow Rs m -1,700 -748 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for ZYDUS LIFESCIENCES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 38.1, an improvement from the EPS of Rs 19.8 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 1,184.9, stands at 31.1 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 6.0 times, while the price to sales ratio stands at 6.1 times.
  • The company's price to cash flow (P/CF) ratio stood at 16.6 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Sales per share (Unadj.) Rs 170.3 194.3
TTM Earnings per share Rs 19.8 38.1
Diluted earnings per share Rs 19.9 38.1
Price to Cash Flow x 18.2 16.6
TTM P/E ratio x 24.7 31.1
Price / Book Value ratio x 2.4 3.8
Market Cap Rs m 412,144 761,065
Dividends per share (Unadj.) Rs 6.0 3.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for ZYDUS LIFESCIENCES

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 2.1x during FY24, from 1.8x during FY23. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 60.2x during FY24, from 20.9x during FY23. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 19.3% during FY24, from 11.4% during FY24. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 24.7% during FY24, from 15.5% during FY23. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 14.2% during FY24, from 8.7% during FY23. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Current ratio x 1.8 2.1
Debtors’ Days Days 94 97
Interest coverage x 20.9 60.2
Debt to equity ratio x 0.0 0.0
Return on assets % 8.7 14.2
Return on equity % 11.4 19.3
Return on capital employed % 15.5 24.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how ZYDUS LIFESCIENCES has performed over the last 5 years, please visit here.

ZYDUS LIFESCIENCES Share Price Performance

Over the last one year, ZYDUS LIFESCIENCES share price has moved up from Rs 602.1 to Rs 1,184.9, registering a gain of Rs 582.8 or around 96.8%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 38,755.3 (down 0.1%). Over the last one year it has moved up from 26,443.1 to 38,755.3, a gain of 12,312 points (up 46.6%).

Overall, the S&P BSE SENSEX is up 21.2% over the year.

(To know more, check out historical annual results for ZYDUS LIFESCIENCES and quarterly results for ZYDUS LIFESCIENCES)

Annual Report FAQs

What is the current share price of ZYDUS LIFESCIENCES?

ZYDUS LIFESCIENCES currently trades at Rs 948.7 per share. You can check out the latest share price performance of ZYDUS LIFESCIENCES here...

What was the revenue of ZYDUS LIFESCIENCES in FY24? How does it compare to earlier years?

The revenues of ZYDUS LIFESCIENCES stood at Rs 199,168 m in FY24, which was up 12.4% compared to Rs 177,120 m reported in FY23.

ZYDUS LIFESCIENCES' revenue has grown from Rs 143,702 m in FY20 to Rs 199,168 m in FY24.

Over the past 5 years, the revenue of ZYDUS LIFESCIENCES has grown at a CAGR of 8.5%.

What was the net profit of ZYDUS LIFESCIENCES in FY24? How does it compare to earlier years?

The net profit of ZYDUS LIFESCIENCES stood at Rs 38,314 m in FY24, which was up 91.4% compared to Rs 20,019 m reported in FY23.

This compares to a net profit of Rs 23,264 m in FY22 and a net profit of Rs 22,056 m in FY21.

Over the past 5 years, ZYDUS LIFESCIENCES net profit has grown at a CAGR of 34.4%.

What does the cash flow statement of ZYDUS LIFESCIENCES reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of ZYDUS LIFESCIENCES reveals:

  • Cash flow from operations increased in FY24 and stood at Rs 32,279 m as compared to Rs 26,888 m in FY23.
  • Cash flow from investments decreased in FY24 and stood at Rs -14,752 m as compared to Rs 15,350 m in FY23.
  • Cash flow from financial activity increased in FY24 and stood at Rs -18,104 m as compared to Rs -44,004 m in FY23.

Here's the cash flow statement of ZYDUS LIFESCIENCES for the past 5 years.

(Rs m)FY20FY21FY22FY23FY24
From Operations29,31532,93921,04526,88832,279
From Investments-10,123-7,246-10,00315,350-14,752
From Financial Activity-15,282-25,477-8,683-44,004-18,104
Net Cashflow3,989-9052,186-1,700-748

What does the Key Ratio analysis of ZYDUS LIFESCIENCES reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of ZYDUS LIFESCIENCES reveals:

  • Operating profit margins witnessed a fall and down at 27.0% in FY24 as against 17.2% in FY23.
  • Net profit margins grew from 11.6% in FY23 to 19.6% in FY24.
  • Debt to Equity ratio for FY24 stood at 0.0 as compared to 0.0 in FY23.

Here's the ratio/financial analysis of ZYDUS LIFESCIENCES for the past 5 years.

 FY20FY21FY22FY23FY24
Operating Profit Margin (%)17.022.121.817.227.0
Net Profit Margin (%)8.215.315.411.619.6
Debt to Equity Ratio (x)0.30.00.00.00.0

 

Equitymaster requests your view! Post a comment on "ZYDUS LIFESCIENCES 2023-24 Annual Report Analysis". Click here!